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We are imminently faced with the challenges of an increasingly aging
population and longer lifespans due to improved health care.
Concomitantly, we are faced with ubiquitous environmental pollution linked
with various health effects and age-related diseases which contribute to
increased morbidity with age. Geriatric populations are rarely considered in
the development of environmental regulations or in toxicology research. Today,
life expectancy is often into one’s 80s or beyond, which means multiple
decades living as a geriatric individual. Hence, adverse health effects and
late-onset diseases might be due to environmental exposures as a geriatric,
and we currently have no way of knowing. Considering aging from a different
perspective, the term “gerontogen” was coined in 1987 to describe chemicals
that accelerate biological aging but has largely been left out of toxicology
research. Thus, we are challenged with a two-faced problem that we can
describe as a “toxic aging coin”; on one side we consider how age affects the
toxic outcome of chemicals, whereas on the other side we consider how
chemicals accelerate aging (i.e. how chemicals act as gerontogens).
Conveniently, both sides of this coin can be tackled with a single animal
study that considers multiple age groups and assesses basic toxicology of
the chemical(s) tested and aging-focused endpoints. Here, I introduce the
concept of this toxic aging coin and some key considerations for how it applies
to toxicology research. My discussion of this concept will focus on the brain, my
area of expertise, but could be translated to any organ system.
KEYWORDS

gerontogen, aging, toxicology, neuroinﬂamation, blood brain barrier (BBB), cellular
senescence

1 Introduction
We are entering a new international paradigm where environmental pollution is
ubiquitous and coinciding with an unprecedented aging population. Today people are
living 50 years longer than in 1950, and ~10% of the global population is geriatric (aged
65+). Further, the United Nations projects by 2030, 20% of the population in developed
nations will be geriatric, with the global population reaching this proportion by 2075
(United Nations et al., 2019; Gu et al., 2021). This dynamic presents new challenges to our
health infrastructure as age-related diseases and comorbidities become increasingly
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Importantly,
neurodevelopment
features
an
initial
overproduction of neurons followed by a period of cell death;
both processes can be affected by toxicants. Hence, we can see
environmental chemicals may disrupt neurodevelopment at
multiple stages with drastically different outcomes (Rodier,
1995; Rice and Barone, 2000; Heyer and Meredith, 2017). The
most studied outcomes of neurodevelopmental toxicology are
neurodevelopmental disorders (e.g. autism spectrum disorder,
attention deﬁcit/hyperactivity disorder) and late-life
neurodegenerative diseases following the Developmental
Origin of Health and Disease (DOHaD) hypothesis (Schmid
and Rotenberg, 2005; Wadhwa et al., 2009; Gluckman et al., 2010;
Patisaul, 2017; Tran and Miyake, 2017; van de Bor et al., 2019).
After birth, our brains continue to grow and change for much of
our lives; typically, our brains are ~80% of the maximum size by
age 3, with the maximum gray matter, subcortical gray, and white
matter volumes reached by age 6, 14, and 30, respectively
(Bethlehem et al., 2022). After maximum brain volume is
reached, regional declines are observed with age and each
region exhibits a different rate of volume decline (Ziegler
et al., 2012; Tamnes et al., 2013; Fuhrmann et al., 2022). After
age 40 the volume of brain ventricles begins to rapidly increase,
and after age 50 the white matter volume rapidly declines with
age (Bethlehem et al., 2022).

prevalent in our populations. For many of these age-related
diseases, environmental pollutants are signiﬁcant contributors
to their etiology and we will continue to see a rise in their
prevalence unless we are able to reduce or remediate
environmental pollution. Compounding this issue, we now
recognize many of these pollutants may act as
gerontogens—chemicals that induce or accelerate the
biological aging process (Martin, 1987). Hence, we are
challenged with a two-faced issue that we can refer to as a
“toxic aging coin”: on the heads side we consider how age
impacts the toxic outcome of a chemical, whereas on the tails
side we consider how chemicals act as gerontogens. Here, I will
discuss how this toxic aging coin applies to brain health, though
this principle could be applied to any organ system. Importantly,
our ability to investigate this toxic aging coin is enhanced by
several key papers from the last decade describing the hallmarks
of aging, hallmarks of brain aging (which are slightly different),
and reviews describing the toxicology of aging (López-Otín et al.,
2013; Sorrentino et al., 2014; Mattson and Arumugam, 2018;
Rackova et al., 2021). This article will focus on the aspects of
aging and gerontogens that are most impactful, and provide
references to reviews that discuss relevant topics in further detail.

2 Heads: Age impacts neurotoxic
effects of chemicals
2.1 The neurovascular unit and bloodbrain barrier across ages

The heads side of this toxic aging coin considers how age can
change the neurotoxic effect of chemicals. From decades of
lifespan research, we recognize the biology of our brains are
distinct across ages which we can summarize simply as young,
adult, or geriatric; a young brain is developing, an adult brain is
mature, and a geriatric brain is degenerating. With these three
distinctions, we can begin to conceptualize how age can alter the
ways chemicals interact with our brains across our lifespan.
Importantly, geriatric populations have largely been left out of
the framework of environmental toxicology and safety
regulations, leaving a huge gap in our understanding the
toxicology of aging. In this Section 1 will discuss the heads
side of the toxic aging coin, and how we as toxicologists
should consider all age groups in our research—young, adult,
and geriatric.
Neurodevelopmental exposures may occur pre- or
postnatally, and the timing of exposure can have critically
different impacts. The development of the nervous system
begins relatively late during embryogenesis, and many of the
mechanisms driving neural development are conserved across
species. After the three main cell layers are formed (endoderm,
mesoderm, ectoderm), the nervous system develops from the
ectoderm during the gastrula stage. Neurodevelopment proceeds
through tightly regulated signaling molecules to direct migration
of neurons and axons to their terminal destinations, which may
be affected by toxicants (Connors et al., 2008; Batool et al., 2019).
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A critical component for distinguishing how environmental
chemicals may impact brain health across ages is the blood brain
barrier (BBB), a functional barrier formed by cells within the
neurovascular unit (NVU). The NVU is made up of
cerebrovascular endothelial cells, pericytes, and astrocytic
endfeet, with neurons and microglia closely associated with
the periphery to stimulate or respond to NVU functions as
needed (Muoio et al., 2014; Liu et al., 2020). The BBB is
formed by cerebrovascular endothelial cells at the start of
angiogenesis during neonatal development (embryonic day
11 in rats), and express proteins that provide roles in
structural, transport, metabolic, and adhesion properties
distinct from endothelial cells in other tissues (Blanchette and
Daneman, 2015). These early blood vessels initially exhibit leaky
properties such as high rates of transcytosis and leukocyte
adhesion molecules (LAMs). Leakiness decreases within the
ﬁrst few days following angiogenesis by endothelial cells,
increasing the complexity of barrier proteins (e.g. TJ-1, ZO-1,
occludin, claudins) and recruiting pericytes, which suppress
endothelial expression of LAMs and transcytosis (Armulik
et al., 2010; Daneman et al., 2010). Astrocyte endfeet cover
almost the entire surface of microcapillaries in the brain, but
astrogliogenesis begins after birth. Importantly, the interaction
between astrocytic endfeet and cerebrovascular endothelial cells
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determines the ﬁnal maturation of the NVU (Wolburg et al.,
2009; Gilbert et al., 2019). Hence, there is a post-natal period
where the NVU is not completely developed and infant brains are
at higher risk for chemical insults. Upon maturation, the NVU/
BBB serve to protect the brain parenchyma from peripheral
blood components through barriers and efﬂux channels, while
also providing nutrients through speciﬁc transport proteins
(Daneman and Prat, 2015).
It is unclear when (or if there is) an age threshold that deﬁnes
when a mature NVU/BBB shifts to a degenerative state. During
aging it is clear there are several phenotypic changes that occur
that contribute to leakiness in the degenerating
cerebrovasculature, including: focal necrosis of endothelium,
decreased endothelial mitochondrial density, increased
pinocytic vesicles, loss of tight junction proteins, loss of
astrocytic endfeet, stiffening of vessel walls, decreased
microvascular density; and smaller capillary lumen size with
greater tortuosity (Zeevi et al., 2010; Marques et al., 2013). These
degenerative changes to the NVU/BBB are believed to contribute
to the etiology of age-associated neurodegenerative diseases (e.g.
Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral
sclerosis), age-associated susceptibility to stroke, white matter
disease, delirium, and other age-associated neurological
conditions. In sum, we exhibit a weaker BBB for a relatively
short window (months) early in our development and for a much
longer time (years to decades) toward the end of our lifespan.
During these periods our brains are susceptible to insult by a
wider variety of chemical insults.

secondary stimuli (e.g. infection, toxicants, stress) (Lyman
et al., 2014; Barrientos et al., 2015). While the number of
microglia does not change with age, the expression of
activation markers including major histocompatibility complex
II (MHC II), CD11b, and Iba-1 increase on a per cell basis and
secrete higher amounts of pro-inﬂammatory cytokines (Lyman
et al., 2014). Normally, neuroinﬂammatory changes in microglia
are transient and return to a resting, ramiﬁed state after the insult
is cleared. Aging may present a context where microglia
activation is not resolved and persists, resulting in a chronic
state of primed microglia and exaggerated responses to noxious
stimuli. Microglia can also recruit astrocytes to participate in
neuroinﬂammation (Godbout and Johnson, 2009). When
activated, astrocytes increase expression of glial ﬁbrillary
protein (GFAP). Depending on context and timing, this
activation may contribute to immunosuppression and tissue
repair, or it may exacerbate inﬂammatory reactions and tissue
damage (Colombo and Farina, 2016). Overall, astrocytes display
a more inﬂammatory phenotype with aging. Importantly, proinﬂammatory cytokines from microglia and astrocytes impair the
integrity of the BBB, altering the resistance of tight junctions,
increasing permeability, and enabling peripheral leukocytes to
enter the brain (Terrando et al., 2011).

3 Tails: Chemicals act as gerontogens
to accelerate biological aging
The tails side of this toxic aging coin considers how chemicals
can accelerate biological aging. The role of genetics account for
10–25% of human lifespan, thus non-genetic, epigenetic, and
environmental factors must play a signiﬁcant role in human
aging (Ruby et al., 2018; van den Berg et al., 2019; Bin-Jumah
et al., 2022). The term “gerontogen” was ﬁrst coined in 1987 by
Dr. George Martin to describe the effect of chemicals inducing or
accelerating biological aging processes in tissues and cells
(Martin, 1987). At the time of this publication, there was a
detrimental lack of reliable aging biomarkers to support
thorough investigation of gerontogens causing aging
phenotypes. Hence, a proper investigation of aging toxicology
had to wait. Since then, there has been a robust research effort to
understand the genetics behind biological aging, and a push to
better understand underlying gene-environment interactions
(Martin, 1997; Rodríguez-Rodero et al., 2011; Moskalev et al.,
2017; Singh et al., 2019). Yet the ﬁeld of toxicology has lagged in
recognizing the signiﬁcance of aging as a toxicological
phenotype, with relatively few studies investigating
gerontogenic effects of chemicals. Today, however, the stage
has been set and toxicology needs to step into the limelight.
Nine hallmarks of aging were identiﬁed and described in 2013,
and a distinct set of hallmarks for brain aging were described in
2018, that now enable proper mechanistic investigation of
gerontogens (López-Otín et al., 2013; Mattson and

2.2 Neuroinﬂammation across lifespan
Neuroinﬂammation is a defensive response to injury or
infection to protect the brain and promote repair, primarily
directed by microglia and astrocytes. Imbalance of
neuroinﬂammation activity early in life can contribute to
development of neurodevelopmental disorders, whereas later
in life it can contribute to development of neurodegenerative
diseases (Molofsky et al., 2012; Chen et al., 2016; Petrelli et al.,
2016; Kim et al., 2020). Clinically, exaggerated
neuroinﬂammation contributes to depression, cognitive
impairment, memory loss, delirium, epilepsy, sickness
behavior, and neurodegenerative diseases (Lyman et al., 2014).
Microglia play the most signiﬁcant role in neuroinﬂammation,
shifting from a ramiﬁed, resting state to an activated phagocytic
state in response to inﬂammatory stimuli, and can remain
activated for long periods of time. While activated, microglia
release pro-inﬂammatory cytokines (e.g. IL-6, TNF-α, IL-1β) and
neurotoxic molecules (e.g. nitric oxide, NO) that contribute to
impaired synaptic plasticity, loss of synapses, neuronal apoptosis,
and long-term neurodegeneration (Lyman et al., 2014). Microglia
become primed due to peripheral inﬂammation, toxicants, or
normal aging, which results in an exaggerated response to
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improvement in age-related pathology (Baker and Petersen,
2019; Zhang et al., 2019; Ogrodnik et al., 2021; Gonzales
et al., 2022; Kim et al., 2022). From a reductionist point of
view; abundance of senescent cells marks aging organs and,
ultimately, aging bodies (Campisi, 2001). Senescent cells
become more abundant with normal aging, are elevated in
neurodegenerative diseases, and age-related symptoms can be
alleviated with their selective removal by senolytic or
senomorphic drugs (Kritsilis et al., 2018; Martínez-Cué and
Rueda, 2020; Sikora et al., 2021; Kim et al., 2022). Thus, this
hallmark is likely the most important for determining if a
toxicant is a gerontogen.
Cellular senescence is characterized by an enlarged, ﬂattened
morphology, altered gene expression (e.g. increased p21, p16INK4a,
C-fos, PCNA), increased senescence associated-β-galactosidase
(SA-β-gal) staining, altered mitochondrial function and
morphology, altered cellular metabolism, and expression of
the senescence associated secretory phenotype (SASP)
(Hernandez-Segura et al., 2018; Martínez-Cué and Rueda,
2020). Several molecular pathways contribute to cells shifting
to a senescent state, though many of the mechanisms for these
pathways have yet to be elucidated. These pathways include, but
are not limited to: DNA damage response, oxidative stress,
telomere shortening, mitochondrial dysfunction, loss of
proteostasis, and endoplasmic reticulum stress (Ben-Porath
and Weinberg, 2005; Hernandez-Segura et al., 2018; Wei and
Ji, 2018; Di Micco et al., 2020).
The impact of cellular senescence on brain health depends on
the type of brain cell, but likely senescence of cells making up the
NVU will have the most signiﬁcant role in brain aging. A
dysfunctional or impaired NVU will result in transient
capillary occlusion, BBB leakage of blood proteins, proinﬂammatory SASP expression, neurovascular uncoupling, and
impaired blood/nutrient supply to the brain, collectively
promoting neurodegeneration (Cortes-Canteli et al., 2015;
Bennett et al., 2018; Petersen et al., 2018; Bryant et al., 2020).
The vast majority of chemical exposures to the brain will be
delivered by the blood; hence the ﬁrst brain cells at risk of
gerontogens will be brain endothelial cells in the
cerebrovasculature (Graves and Baker, 2020). Senescent
endothelial cells shift their phenotype to express more surface
leukocyte adhesion molecules (VCAM-1, ICAM-2, MAdCAM1) and generate a proinﬂammatory environment to recruit
peripheral immune cells to the senescent tissue, contributing
to transient capillary occlusion (Gorgoulis et al., 2005; Lasry and
Ben-Neriah, 2015; Bryant et al., 2020). BBB leakage, evidenced by
increased extravasation of IgG and decreased expression of tight
junction proteins, is another critical effect of aging on the NVU
which likely precedes onset of neurodegenerative diseases
(Pelegri et al., 2007; Bake et al., 2009; Yamazaki et al., 2016).
Astrocytes can become pathogenic when senescent (Cohen and
Torres, 2019). Evidence shows increased proportion of senescent
astrocytes in the frontal cortex of AD patients and senescent

Arumugam, 2018). Further, several animal models have been
developed for rigorous aging studies ranging from C. elegans to
ﬁsh to rodents (Holtze et al., 2021). With the advent of these
aging hallmarks and research models, toxicologists now have the
tools to mechanistically investigate gerontogens as a class of
chemicals. In this Section 1 will discuss the tails side of this toxic
aging coin perspective, and how we as toxicologists can capitalize
on the available resources to investigate how chemicals may act as
gerontogens, and I will note key review articles where further
discussion may be warranted.
An aging brain manifests as deﬁcits in learning and memory,
attention, sensory perception, motor coordination, decisionmaking speed, and cognitive function (Yankner et al., 2009;
Machado, 2020). Many of these are observed in well-known
age-related neurodegenerative diseases (e.g. Alzheimer’s disease,
Parkinson’s disease, amyotrophic lateral sclerosis, stroke). With
our rapidly growing geriatric population we can expect to see a
similar
signiﬁcant
increase
in
these
age-related
neurodegenerative diseases. It is projected we will see the
number of people diagnosed with Alzheimer’s disease more
than double in the next 30 years from ~ 5 million today to
more than 12 million (Alzheimer’s Association, 2016). Similar to
aging, these neurodegenerative diseases are believed to have a
signiﬁcant environmental inﬂuence, with only 5–10% of cases
linked to genetic mutations driving their etiology (Bertram and
Tanzi, 2005; Philstrøm et al., 2018). Faced with this societal
challenge, it is imperative we understand how environmental
chemicals contribute to brain aging and age-related
neurodegenerative diseases and ﬁnd ways to prevent or reduce
exposures to such chemicals (Cannon and Greenamyre, 2011;
Cicero et al., 2017).
The deﬁned hallmarks of brain aging and that of peripheral
tissues are slightly different. While there is quite a bit of overlap,
two hallmarks of aging in peripheral tissues are still emerging in
the context of brain aging, but are likely particularly relevant for
the brain’s glial cells; cellular senescence and telomere attrition.
Given that glial cells make up ~50% of brain cells and displayed
the strongest effect of differential gene expression in aging, it is
probable these glial cells will have stronger deterministic effects
in aging than neurons (Soreq et al., 2017).

3.1 Contributions of cellular senescence
to brain aging
Perhaps the most important hallmark for assessing
gerontogenic effects of chemicals is cellular senescence,
deﬁned as a state of permanent cell cycle arrest, as it is a
terminal cellular phenotype that contributes to tissue/organ
aging (López-Otín et al., 2013; Muñoz-Espín and Serrano,
2014; Hernandez-Segura et al., 2018; González-Gualda et al.,
2021). This view is supported by various studies using senolytics
to selectively induce apoptosis in senescent cells and showing
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enables assessing how toxic effects are different across the age
groups, and on the other side, it enables assessing how toxicants
affect aging hallmarks.

astrocytes can induce neuronal apoptosis or synaptic dysfunction
(Pertusa et al., 2007; Bhat et al., 2012; Miranda et al., 2012).
Importantly, one study demonstrated the selective clearance of
senescent astrocytes prevented tau deposition and degeneration
of hippocampal and cortical neurons in an AD mouse model
(Bussian et al., 2018). Similarly, microglia can become senescent
and contribute to neuroinﬂammation and neurodegeneration,
though these glia have not been as extensively studied and it is
unclear if there is a distinction necessary for senescent vs.
dystrophic microglia (Angelova and Brown, 2019). Aging
microglia were initially identiﬁed by morphology in brains of
aged individuals, and have subsequently been shown to exhibit
impaired motility, iron accumulation, DNA damage
accumulation, telomere shortening, and SASP-like changes in
cytokine production (Streit, 2004; Sierra et al., 2007; Hayashi
et al., 2008; von Bernhardi et al., 2015; Flanary and Streit, 2004;
Orre et al., 2014; Simmons et al., 2007). Given the abundance of
evidence for cellular senescence in brain aging and
neurodegenerative diseases, and the growing evidence for
senolytics as a preventative or therapeutic strategy for these
conditions, it should be added to the hallmarks of brain aging.
Further, we need more toxicology-based research to identify
which chemicals contribute to cellular senescence and what
senescent mechanisms or pathways they induce.
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4 Concluding remarks
Considering the new societal shift we are imminently facing
with a large geriatric population, we need a similar shift in
toxicology research to investigate how chemicals interact with
this toxic aging coin. Both sides of the toxic aging coin will be
imminently relevant and important to the health and success of
our societies. We need more research groups investigating this
intersection of toxicology and aging for all major organs. If all
three age groups (young, middle-aged, geriatric) are included in a
toxicology study, one can readily consider both sides of the toxic
aging coin within the same study; on one side, this study design
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